Literature DB >> 35305851

Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.

Bradley D Stein1, Brendan Saloner2, Rose Kerber3, Mark Sorbero4, Adam J Gordon5.   

Abstract

STUDY
OBJECTIVE: Buprenorphine treatment for opioid use disorder provided in the emergency department with subsequent buprenorphine treatment by community prescribers is associated with improved outcomes, but the frequency with which this occurs is unknown. We examined the rates of subsequent buprenorphine treatment for buprenorphine-naïve individuals filling buprenorphine prescriptions from emergency physicians and initiated buprenorphine treatment and how such rates varied before and during the coronavirus disease 2019 (COVID-19) pandemic.
METHODS: Using pharmacy claims capturing an estimated 92% of prescriptions filled at US retail pharmacies, we identified buprenorphine prescriptions filled between February 1, 2019, and November 30, 2020, written by emergency physicians. In this observational study, we calculated the rate at which patients subsequently filled buprenorphine prescriptions from other nonemergency clinicians, the frequency with which subsequent filled prescriptions were from different types of prescribers, and the changes in the rates of subsequent prescriptions following the declaration of the COVID-19 public health emergency.
RESULTS: We identified 22,846 prescriptions written by emergency physicians and filled by buprenorphine-naïve patients. They were most commonly paid for by Medicaid and were in metropolitan counties; 28.5% of patients subsequently filled buprenorphine prescriptions written by other clinicians. Adult primary care physicians and advanced practice providers (eg, physician assistants and nurse practitioners) were responsible for most of the subsequent prescriptions. The rates of subsequent prescriptions were 3.5% lower after the COVID-19 public health emergency declaration.
CONCLUSION: The majority of patients filling buprenorphine prescriptions written by emergency physicians do not subsequently fill prescriptions written by other clinicians, and the rates of subsequent prescriptions were lower after the declaration of the COVID-19 public health emergency. These findings highlight the need for a system of care that improves buprenorphine treatment continuity of care for patients with opioid use disorder from emergency settings to community treatment providers.
Copyright © 2022 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35305851      PMCID: PMC9038689          DOI: 10.1016/j.annemergmed.2022.01.042

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   6.762


  47 in total

1.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

2.  Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance.

Authors:  Alexander M Ponizovsky; Anatoly Margolis; Ludmila Heled; Paula Rosca; Irena Radomislensky; Alexander Grinshpoon
Journal:  Subst Use Misuse       Date:  2010       Impact factor: 2.164

3.  Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program.

Authors:  Neel Koyawala; Rachel Landis; Colleen L Barry; Bradley D Stein; Brendan Saloner
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

4.  A State Financial Incentive Policy to Improve Emergency Department Treatment for Opioid Use Disorder: A Qualitative Study.

Authors:  Austin S Kilaru; Su Fen Lubitz; Jessica Davis; Whitney Eriksen; Sari Siegel; David Kelley; Jeanmarie Perrone; Zachary F Meisel
Journal:  Psychiatr Serv       Date:  2021-02-17       Impact factor: 3.084

5.  Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department.

Authors:  Kathryn Hawk; Jason Hoppe; Eric Ketcham; Alexis LaPietra; Aimee Moulin; Lewis Nelson; Evan Schwarz; Sam Shahid; Donald Stader; Michael P Wilson; Gail D'Onofrio
Journal:  Ann Emerg Med       Date:  2021-06-22       Impact factor: 5.721

6.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

7.  Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment.

Authors:  S M Giacomuzzi; Y Riemer; M Ertl; G Kemmler; H Rössler; H Hinterhuber; M Kurz
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

8.  Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic.

Authors:  Kristin M Holland; Christopher Jones; Alana M Vivolo-Kantor; Nimi Idaikkadar; Marissa Zwald; Brooke Hoots; Ellen Yard; Ashley D'Inverno; Elizabeth Swedo; May S Chen; Emiko Petrosky; Amy Board; Pedro Martinez; Deborah M Stone; Royal Law; Michael A Coletta; Jennifer Adjemian; Craig Thomas; Richard W Puddy; Georgina Peacock; Nicole F Dowling; Debra Houry
Journal:  JAMA Psychiatry       Date:  2021-04-01       Impact factor: 21.596

9.  Common themes in early state policy responses to substance use disorder treatment during COVID-19.

Authors:  Barbara Andraka-Christou; Kathryn Bouskill; Rebecca L Haffajee; Olivia Randall-Kosich; Matthew Golan; Rachel Totaram; Adam J Gordon; Bradley D Stein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

10.  Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.

Authors:  Jake R Morgan; Bruce R Schackman; Zoe M Weinstein; Alexander Y Walley; Benjamin P Linas
Journal:  Drug Alcohol Depend       Date:  2019-05-03       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.